Opko Health, Inc. · NASDAQ:OPK
Opko Health — Investor Presentation (January 2024)
26 slides from Opko Health's investor presentation, Jan 4, 2024
Slide 1: OPKO Corporate Presentation January 2024
OPKO Corporate Presentation JANUARY 2024
Slide 2: Forward Looking Statements
Forward Looking Statements Forward Looking Statements This presentation contains “forward-looking statements," as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as “expects,” "plans," "projects," “will,” “may,
Slide 3: Our vision
Our vision 000 * ACCOMPLISHED INDUSTRY ESTABLISHED NEXT- PROVEN MANAGEMENT LEADING GLOBAL GENERATION TECHNOLOGIES TEAM WITH LONG PARTNERS MARKETS PRODUCTS TRACK RECORD WITH UNMET NEED
Slide 4: Business transformation continues to unleash OPKO's potential
Business transformation continues to unleash OPKO’s potential FDA approval positions NGENLA™ as the leading long-acting growth hormone product partnered with Pfizer and now approved in more than 40 markets worldwide Growth of multispecific antibody pipeline through advancement and partnering creates
Slide 5: Building a leading portfolio of next-generation therapies in fast-growing segments
Building a leading portfolio of next-generation therapies in fast-growing segments GROWING COMMERCIAL HGH FRANCHISE CONTINUED FOCUS ON BIOREFERENCE NGENLA™ long-acting efficacy to reshape the market PROFITABILITY Estimated $5.5 billion market expected to expand by —— 41% improvement of operating los
Slide 6: Leadership team with unprecedented experience
Leadership team with unprecedented experience 0.9 & Phil Frost CEO and Chairman Former Chairman and Vice Chairman of Teva Former Chairman and CEO of IVAX teva IvAx Jane Hsiao Chief Technical Officer and Vice Chairman Former Vice Chairman- Technical Affairs of IVAX Former Chairman, CEO and President
Slide 7: Addressing Established Markets with Next-Generation Solutions
Addressing Established Markets with Next-Generation Solutions LEUKEMIA AND LYMPHOMAS SOLID TUMOR CANCERS DISEASE HUMAN GROWTH AREA HORMONE DEFICIENCY sie *5.58 980,000+ 140,000- GLOBAL ANNUAL ANNUAL MARKET' U.S. CASES? U.S. CASES? UNMET NGENLA™ offers Multispecific treatments offer potential for dee
Slide 8: Expanding OPKO's global footprint through partnerships
Expanding OPKQ’s global footprint through partnerships Pfizer > MERCK INDUSTRY- LEADING PARTNERS Track record of partnering with world-leading organizations on attractive terms SOUGHT OUT SCIENCE OPKO’s scientific expertise and leading multispecific position continues to offer value VIFOR FRESENIUS
Slide 9: Preparing for global rollouts and offsetting R&D costs with industry-leading partners
Preparing for global rollouts and offsetting R&D costs with industry-leading partners Pfizer > MERCK & m EBV NANOPARTICLE COVID-19 NGENLA VACCINE MULTISPECIFIC ELIGIBLE FOR ADDITIONAL ELIGIBLE FOR UP TO ELIGIBLE FOR UP TO *100m *872.5M *168m IN MILESTONE PAYMENTS FOR IN TOTAL MILESTONE PAYMENTS PLUS
Slide 10: Robust pipeline for well-understood diseases in need of next-generation treatments
Robust pipeline for well-understood diseases in need of next-generation treatments PRODUCT INDICATION PRECLINICAL PHASE 4 PHASE 2 PHASE 3 PARTNER r (Pediatric) —— . oO ‘ | womee tomer ceceny NGENLA’ (Adults) GLOBAL REGISTRATION STRATEGIES UNDERWAY Pfizer 5 Tetraspecific LASER* Treatment of Solid Tum
Slide 11: Human Growth Hormone Franchise
Human Growth Hormone Franchise
Slide 12: Focus on fast-growing markets with differentiated next-generation therapies
Focus on fast-growing markets with differentiated next-generation therapies WE BELIEVE NGENLA™ POSITIONED TO GAIN SIGNIFICANT U.S. AND WORLDWIDE SHARE BETTER ADHERENCE Market to consolidate from 7 daily treatments to 3 long-acting therapies 1. "Human Growth Hormone Market Size Grand View Research, G
Slide 13: Next-generation NGENLA poised to capture significant share of growing global market
Next-generation NGENLA™ poised to capture significant share of growing global market EXPANDING SHARE OF GROWING MARKET TODAY FUTURE BBE ooswy treatments | | LONG-ACTING TREATMENTS CURRENT MARKET Market expected to grow by up to 12.3% S556 $ annually? on improved B adherence . 7 Estimated global hgH
Slide 14: Continued upside from Pfizer partnership in 2024 and beyond
Continued upside from Pfizer partnership in 2024 and beyond INDICATION STATUS COMMERCIAL Pfizer U.S. and European approval of adult indication would unlock additional Growth Hormone Deficiency (Pediatric) Growth Hormone GLOBAL REGISTRATION STRATEGIES $ IN MILESTONE Deficiency (Adults) UNDERWAY M pay
Slide 15: Innovation Pipeline
Innovation Pipeline
Slide 16: Proprietary approaches with broad disease applicability
Proprietary approaches with broad disease applicability IMMUNO- ONCOLOGY INFECTIOUS DISEASE Strong IP around core technologies & y y | Broad optionality in diseases not addressable by older modalities ; ; Strong synergies across Multivalent nanoparticle programs via shared Multispecific antibodies M
Slide 17: Addressing large and critical patient needs in oncology with therapies that attack multiple disease drivers
Addressing large and critical patient needs in oncology with therapies that attack multiple disease drivers ESTABLISHED GLOBAL MARKETS WITH UNMET NEED NEXT-GENERATION THERAPIES 000 Multispecific antibodies designed to bind to two T cell antigens and two tumor antigens SOLID TUMORS?" BLOOD CANCERS? $
Slide 18: Tetraspecific LASER Antibodies for Immuno-Oncology
Tetraspecific LASER Antibodies for Immuno-Oncology LUNG, PROSTATE, BREAST, UTERINE, B CELL MALIGNANCIES: COLON AND OTHER SOLID CANCERS LYMPHOMA/LEUKEMIA Lead candidate with IND MDX2001 In IND-enabling phase MDX2003 submission expected in First Half 2024 copes Dual T-cell signaling + cp28 Target 1 st
Slide 19: Tackling EBV, one of the world's most common viruses with no approved vaccines or therapies
Tackling EBV, one of the world’s most common viruses with no approved vaccines or therapies NEXT-GENERATION THERAPIES 000 Nanoparticle EBV candidate targeting four viral proteins PROVEN TECHNOLOGIES e . - Next-generation vaccine ag for cancer prevention a, Gardasil a successful model for V preventat
Slide 20: Improving treatment of infectious disease through multispecifics that address viral evolution
Improving treatment of infectious disease through multispecifics that address viral evolution NEXT-GENERATION THERAPIES ESTABLISHED GLOBAL MARKETS WITH UNMET NEED ooo Multispecific antibodies platform CovID-19 | NIH) HIV allows for the rational selection blir bed RESEARCH FULLY FUNDED PHASE 1 TRIAL
Slide 21: Diagnostics Division
Diagnostics Division
Slide 22: Continued focus on improving profitability through strategic growth and cost reduction
Continued focus on improving profitability through strategic growth and cost reduction IMPROVING PRODUCTIVITY EXPANDING SERVICE LINES SEGMENTS OPRER STRAZEGIC AND ENHANCING INNOVATION THROUGH EXISTING GROWTH IN HIGH-VALUE SPECIALTY CAPABILITIES TESTING SEGMENTS BEST-IN-CLASS ONCOLOGY TESTING PORTFOL
Slide 23: Operating Businesses
Operating Businesses
Slide 24: Operating units generating additional income for reinvestment
Operating units generating additional income for reinvestment IRELAND GLOBALFINANCIALS THROUGH Q3 ‘23 $681.6m TOTAL SALES $91.7m RAYALDEE SALES U.S. MEXICO TOTAL SALES BY COUNTRY ISRAEL U.S.: $463.0M Spain: $16.4M Ireland: $121.2M Israel: $9.4M Chile: $52.4M Other: $1.7M Mexico: $17.4M CHILE vf
Slide 25: Key Takeaways
Key Takeaways
Slide 26: Transformative 2023 serves as springboard for further growth in 2024
Transformative 2023 serves as springboard for further growth in 2024 2023 ACCOMPLISHMENTS 4 NGENLA™ receives U.S. FDA approval W New partnership agreements signed with over $1 billion in potential milestone payments we Continued progress on creating efficiencies and improving profitability in diagno